The Truth Is In…

I say "in writing veritas."  MarketWatch asked me to write an article about one's investment strategy in the interest rate environment on the horizon.

The Truth Is In

Who ever said, “vino veritas” (in wine, there is truth), hasn’t written enough. I say, “in writing veritas.”   MarketWatch asked me to write an article about one’s investment strategy in the interest rate environment on the horizon.  When I first sat down to write, I thought that I was a bit neutral on the direction of interest rates. However, by the time I finished (as you’ll see), it was painfully obvious that interest rates are more likely to go down than up. It’s a story of global prosperity that has been in part prepped up by finite sources (mostly debt).

I would not bet my career or even a bottle of fine beer (Fat Tire – those in Colorado will know), but there are too many “uncertainties” on the horizon for higher interest rates.  In the article, I offered two stocks, Glaxosmithkline (GSK) and Johnson & Johnson (JNJ)  that should do well in any interest rate environment.

Please read the following important disclosure here.

Related Articles

The Magnificent 7 and the Dangers of Market Hype

The Magnificent 7 and the Dangers of Market Hype

Despite the S&P 500 showing gains in the mid-teens, the average stock on the market is either up slightly or flat for the year.

Understanding Today’s Economic Landscape

Interest rates that stay low and actually keep declining for almost a quarter of a century slowly propagate deep into the fabric of the economy.

From Bull to Sideways Markets to Nvidia

I discussed my condensed views on the stock market, economy, and our investment strategy in a letter to IMA clients.

Traditions, Investment Conferences and Presentations

Investment conferences are the constants in my life. This year, we heard 24 presentations in three days at VALUEx Vail.

Leave a Comment